Adimmune Corp, a vaccine manufacturer based in Taiwan, could be listed on the stock market by March, the company announced today.

The company, which is in the process of completing the clinical test of an influenza vaccine in Europe with Netherlands-based Crucell, said that the Taiwan Stock Exchange approved its application.

The H5N1 vaccine has completed animal testing and will go into human testing in the second quarter of this year.

Adimmune is currently building a cell culture plant in the Central Taiwan Science Park in order to produce an Enterovirus 71 vaccine and vaccines against diseases such as dengue fever and Japanese encephalitis.

Construction on the facility is expected to be completed in 2014 and to start production in 2015, reports Central News Agency.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Over 3 million vaccine doses are expected to be produced annually, which will generate NT$2 billion ($66 million) in production value per year, the company said in December last year.


Image: Adimmune is in the process of completing a clinical test of an H5N1 vaccine in Europe.